Price Alert

Esperion Therapeutics Inc... (ESPR)

NASDAQ: ESPR · Real-Time Price · USD

2.07

0.13 (6.70%)

At close: Aug 14, 2025, 3:59 PM

2.09

0.97%

Pre-market: Aug 15, 2025, 07:19 AM EDT

Esperion Therapeutics Statistics

Share Statistics

Esperion Therapeutics has 198.2M shares outstanding. The number of shares has increased by 1.01% in one year.

Shares Outstanding	198.2M
Shares Change (YoY)	1.01%
Shares Change (QoQ)	0.18%
Owned by Institutions (%)	57.76%
Shares Floating	193.62M
Failed to Deliver (FTD) Shares	326
FTD / Avg. Volume	0.01%

Short Selling Information

The latest short interest is 22.1M, so 11.15% of the outstanding shares have been sold short.

Short Interest	22.1M
Short % of Shares Out	11.15%
Short % of Float	11.2%
Short Ratio (days to cover)	6.98

Valuation Ratios

The PE ratio is -7.96 and the forward PE ratio is -187. Esperion Therapeutics's PEG ratio is 0.09.

PE Ratio	-7.96
Forward PE	-187
PS Ratio	1.24
Forward PS	1.1
PB Ratio	-1.06
P/FCF Ratio	-17.18
PEG Ratio	0.09

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Esperion Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of -1.52.

Current Ratio	1.37
Quick Ratio	0.99
Debt / Equity	-1.52
Debt / EBITDA	78.11
Debt / FCF	-24.66
Interest Coverage	0.92

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$1.09M
Profits Per Employee	$-170.21K
Employee Count	304
Asset Turnover	0.97
Inventory Turnover	0.73

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 0.54% in the last 52 weeks. The beta is 0.82, so Esperion Therapeutics's price volatility has been higher than the market average.

Beta	0.82
52-Week Price Change	0.54%
50-Day Moving Average	1.23
200-Day Moving Average	1.66
Relative Strength Index (RSI)	71.42
Average Volume (20 Days)	4,788,062

Income Statement

In the last 12 months, Esperion Therapeutics had revenue of 332.31M and earned -51.74M in profits. Earnings per share was -0.28.

Revenue	332.31M
Gross Profit	263.71M
Operating Income	54.4M
Net Income	-51.74M
EBITDA	7.57M
EBIT	7.51M
Earnings Per Share (EPS)	-0.28

Full Income Statement

Balance Sheet

The company has 144.76M in cash and 591.21M in debt, giving a net cash position of -446.45M.

Cash & Cash Equivalents	144.76M
Total Debt	591.21M
Net Cash	-446.45M
Retained Earnings	-1.6B
Total Assets	324.03M
Working Capital	47.81M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -23.65M and capital expenditures -317K, giving a free cash flow of -23.97M.

Operating Cash Flow	-23.65M
Capital Expenditures	-317K
Free Cash Flow	-23.97M
FCF Per Share	-0.13

Full Cash Flow Statement

Margins

Gross margin is 79.36%, with operating and profit margins of 16.37% and -15.57%.

Gross Margin	79.36%
Operating Margin	16.37%
Pretax Margin	-15.57%
Profit Margin	-15.57%
EBITDA Margin	2.28%
EBIT Margin	16.37%
FCF Margin	-7.21%

Dividends & Yields

ESPR does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ESPR is $4, which is 116.2% higher than the current price. The consensus rating is "Buy".

Price Target	$4
Price Target Difference	116.2%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-6.88
Piotroski F-Score	2